A collection of TBL summaries relevant to Intensive Care Medicine

PLUS Study

Balanced Multielectrolyte Solution versus Saline in Critically Ill Adults Finfer S, NEJM, 2022; DOI: 10.1056/NEJMoa2114464 Clinical Question In critically ill adults does the use of a balanced multielectrolyte solution (BMES, Plasmalyte 148), as opposed to 0.9% Sodium Chloride, for fluid resuscitation and therapy result in reduced 90 day mortality? Background Fluid administration is a key component of critical care therapy […]

Continue reading »

PALACS

  Posterior left pericardiotomy for the prevention of atrial fibrillation after cardiac surgery Mario Gaudino, The Lancet Dec 4 2021; 398: 2075–83 https://doi.org/10.1016/S0140-6736(21)02490-9 Clinical Question In selected patients undergoing cardiac surgery, does posterior left pericardiotomy compared with usual care, reduce the incidence of postoperative atrial fibrillation? Background Atrial fibrillation is common following cardiac surgery with approximately one-third of patients developing […]

Continue reading »

CONTROLING

Individualised versus conventional glucose control in critically-ill patients: the CONTROLING study—a randomized clinical trial Bohé. Intensive Care Medicine 2021. https://doi.org/10.1007/s00134-021-06526-8 Clinical Question In critically unwell adults does targeting individualised glycaemic control compared to glycaemia < 180 mg/dL improve 90 day mortality? Background Hyperglycaemia has been shown to result in worse outcomes in the critically ill, especially in non-diabetic patients In […]

Continue reading »

VAM-IHCA

Effect of Vasopressin and Methylprednisolone vs Placebo on Return of Spontaneous Circulation in Patients With In-Hospital Cardiac Arrest: A Randomized Clinical Trial Anderson et al. JAMA 2021. doi:10.1001/jama.2021.16628 Clinical Question In adult patients suffering an in-hospital cardiac arrest (IHCA) does the use of vasopressin and methylprednisolone compared to a placebo result in increased rates of return of spontaneous circulation (ROSC)? […]

Continue reading »

RECOVERY REGEN-COV

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial @PeterHorby. medRxiv pre-print 2021 doi: https://doi.org/10.1101/2021.06.15.21258542 Clinical Question In hospitalised patients with COVID-19, does the addition of monoclonal antibodies REGEN-COV (carsirivimab & imdevimab) to standard care, compared with standard care alone, improve 28 day mortality? Background Monoclonal antibodies have been shown to be […]

Continue reading »
1 6 7 8 9 10 42